PA-WESTINGHOUSE-ELECTRIC
22.2.2024 10:01:28 CET | Business Wire | Press release
Westinghouse organized the 5th annual VVER Fuel Forum in Bratislava with representatives from six utilities. The forum, hosted by Slovenské elektrárne, provided the opportunity to share experiences and best practices with VVER-1000 and VVER-440 fuel deployment in operating reactors.
Westinghouse offered detailed briefings on fuel licensing, NOVA E-6 design enhancements, fabrication plant upgrades, delivery and operations.
As the leader of the European Union-funded APIS project (Accelerated Program for Implementation of secure VVER fuel Supply), Westinghouse also presented additional information on next-generation fuel design development and a harmonized approach for VVER fuel licensing.
“We are pleased to host so many colleagues in Bratislava to discuss the critical topic of fuel diversification,” said Branislav Strýček, Chairman of the Board of the Board of Directors and General Director of Slovenské elektrárne. “We are currently going through the preparation of the documentation in Slovakia for new VVER-440 fuel and expect to finish the licensing process by 2026-2027. We are looking forward to achieving diversification of fuel sources as we expand the lifetime operations of our nuclear plants.”
“In Ukraine, we started the licensing process for the Westinghouse VVER-440 fuel in 2022 and, thanks to great cooperation, we successfully completed it within 1.5 years. We received the first fuel load for Rivne unit 2 last September, ahead of the originally planned schedule. Our two units will be operating later this year with the new fuel, which has been performing well after six months," said Olexandr Depenchuk, Director for Nuclear and Radiation Safety of Energoatom. “The joint efforts of Energoatom and Westinghouse have enabled us to end our dependence on Russian fuel.”
“We recommend expediting the ongoing fuel diversification efforts in the context of the REPowerEU Plan launched in May 2022 and the global energy disruption caused by Russia’s invasion of Ukraine,” said Stefano Ciccarello, Acting Director General of the Euratom Supply Agency.
In Finland, Fortum is pursuing mechanical operating experiences with the new fuel type, after a test assembly manufactured by Westinghouse was loaded into the Loviisa-2 reactor last year. “The changes done in the design of the VVER-440 fuel we originally used in Loviisa in the early 2000s improved the fuel behavior and performance. We are currently reviewing the licensing and manufacturing documentation of the first new fuel deliveries and expect this work to be ready this summer,” said Iiro-Ville Lehtinen, Fortum Project Manager.
“Westinghouse will deliver the first batch of VVER-440 fuel assemblies to the Dukovany nuclear power plant at the end of this year. The deliveries for Temelín will follow a few months after Dukovany, as mutually agreed based on the refueling schedule,” said Rostislav Štaubr, Head of Nuclear Fuel Procurement of CEZ.
“We really appreciate our collaboration with Westinghouse,” said Svilena Nikolova, Head of Legal and Commercial Department of Kozloduy Nuclear Power Plant. “The diversification that has been obtained in terms of nuclear fuel supply is of great importance for the power plant. As Kozloduy celebrates its 50th anniversary this year, we will also receive the first load of new VVER-1000 fuel from Westinghouse for our unit 5.”
“We are delighted to share the achievements of this key program to ensure energy security and supply diversification for our customers in the region,” said Tarik Choho, Westinghouse President of Nuclear Fuel. “There were many great achievements in the past years and still a lot of work ahead of us. As the only European VVER fuel manufacturer, we are committed to delivering what is required by our customers.”
Westinghouse is a leading supplier of nuclear fuel, providing a uniquely diversified portfolio in the industry across nuclear reactor types, including PWR, BWR, AGR and VVER. Through our world-class manufacturing facilities in Sweden, the U.K. and the U.S., we focus on delivering innovative fuel technologies to meet our customers’ needs for lower fuel cycle costs, increased operational flexibility and efficiency, diversity of supply and accident-tolerant products. Learn more about our advanced fuel capabilities and how they relate to different reactors around the world: Westinghouse Nuclear > Nuclear Fuel.
Westinghouse Electric Company is shaping the future of carbon-free energy by providing safe, innovative nuclear technologies to utilities globally. Westinghouse supplied the world’s first commercial pressurized water reactor in 1957 and the company’s technology is the basis for nearly one-half of the world's operating nuclear plants. Over 135 years of innovation make Westinghouse the preferred partner for advanced technologies covering the complete nuclear energy life cycle. For more information, visit www.westinghousenuclear.com and follow us on Facebook, LinkedIn and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222283969/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
